GlassScriptPhysician profile
Keith Isaac Block
NPI 1538208764
$5,128.70
in general payments reported to CMS, 2019-2025
35 companies · $1,119 in 2025
The $1,119 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,543 · 2020: $264 · 2021: $287 · 2022: $342 · 2023: $708 · 2024: $865 · 2025: $1,119.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,360 · Education: $332.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,360.00 |
| Education | $331.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $996.86 | 2019-2023 | Verzenio, Jaypirca |
| Pfizer INC. | $509.04 | 2019-2025 | |
| Genentech USA, INC. | $500.75 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $475.64 | 2019-2025 | Imfinzi, Calquence, Lynparza |
| E.R. Squibb & Sons, L.L.C. | $282.36 | 2019-2025 | Opdivo |
| Merck Sharp & Dohme LLC | $226.21 | 2019-2024 | Keytruda |
| Gilead Sciences, INC. | $212.94 | 2019-2025 | Trodelvy |
| Novartis Pharmaceuticals Corporation | $208.77 | 2019-2025 | |
| Puma Biotechnology, INC. | $164.68 | 2019-2024 | |
| Array Biopharma INC | $163.56 | 2024-2025 | Lorbrena, Braftovi, Mektovi |
| Daiichi Sankyo INC. | $160.86 | 2023-2025 | Enhertu, Datroway |
| Tempus Ai, INC | $157.64 | 2024-2025 | Xt Cdx |
| Glaxosmithkline, LLC. | $120.36 | 2024-2025 | Ojjaara |
| Abbvie INC. | $117.80 | 2020-2025 | |
| Emd Serono, INC. | $109.40 | 2019-2020 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $94.18 | 2024 | Reblozyl, Pomalyst |
| Amgen INC. | $86.59 | 2021-2023 | Lumakras, Xgeva, Vectibix |
| Takeda Pharmaceuticals U.S.A., INC. | $62.14 | 2020-2025 | Fruzaqla |
| Tersera Therapeutics LLC | $58.56 | 2024-2025 | Zoladex, Xermelo |
| Astellas Pharma US INC | $51.64 | 2025 | Vyloy, Xtandi |
| Incyte Corporation | $47.20 | 2023-2025 | Jakafi, Monjuvi |
| Janssen Biotech, INC. | $46.17 | 2024-2025 | Tecvayli, Talvey, Darzalex |
| Invivyd INC | $35.92 | 2025 | Pemgarda |
| Celltrion USA INC. | $24.91 | 2023 | Vegzelma |
| Menarini Silicon Biosystems, INC. | $23.60 | 2024 | |
| Servier Pharmaceuticals LLC | $22.64 | 2025 | |
| Pharmacosmos Therapeutics INC. | $21.93 | 2024 | Cosela |
| Myriad Genetic Laboratories, INC. | $21.54 | 2025 | Myrisk |
| Dexcom, INC. | $21.48 | 2025 | Dexcom G6 Transmitter |
| Pharmacyclics LLC, An Abbvie Company | $21.15 | 2023 | Imbruvica |
| Mylan Institutional INC. | $19.56 | 2019 | |
| Coherus Oncology, INC. | $18.55 | 2024 | |
| Dova Pharmaceuticals | $16.94 | 2019 | |
| Advanced Accelerator Applications | $15.39 | 2020 | |
| Tactile Systems Technology INC | $11.74 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Keith Block listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.